Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Assessment on life quality of patients with chronic hepatitis B after three types of antiviral treatment

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

Application of Quality of Life Assessment in the Efficacy Evaluation of Interferon in the Treatment of Chronic Hepatitis C

Evaluation of Health Related Quality of Life with Treatment of Lamivudine in Chronic Hepatitis B Patients.

Effect of interferon therapy on quality of life in patients with chronic hepatitis B

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

Study on the Efficacy and Related Factors of Antiviral Therapy in Chronic Hepatitis B

Quality of Life and Its Influential Factors in Outpatients with Chronic Hepatitis B or C

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

Health-Related Quality Of Life And Its Influencing Factors In Patients With Hepatitis B: A Cross-Sectional Assessment In Southeastern China

Relationship Between the Antiviral Effect and Changes in Helper T (th) Cytokine Levels in the Treatment of Chronic Hepatitis B Using Lamivudine Combined with Alpha Interferon

Effect on Prognosis with Different Treatment Measurement for 618 Cases of Chronic Severe Hepatitis B

[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].

Experience of Patients with Chronic Hepatitis B during Antiviral Therapy

Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study

The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis

[525] EVALUATION OF EFFICIENCY OF SEQUENTIAL THERAPY WITH INTERFERON AND LAMIVUDINE FROM CHANGES OF HBV Cccdna IN LIVER IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS

[The Relationship Between HBV Genotypes and the Efficacy of Antiviral Therapies in Hepatitis B E Antigen- Positive Patients].

[Clinical value of health-related quality of life evaluation in community patients with hepatitis B]